Heart Failure in Rheumatoid Arthritis: Clinical Implications.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-17 DOI:10.1007/s11897-024-00682-w

Alexis Zambrano Zambrano, Hector Del Río Zanatta, Andrea González Espinoza, Brian Bernal Alferes, Kevin Zambrano Zambrano, Julio Martinez Salazar, Carlos Haroldo Ixcamparij Rosales

{"title":"Heart Failure in Rheumatoid Arthritis: Clinical Implications.","authors":"Alexis Zambrano Zambrano, Hector Del Río Zanatta, Andrea González Espinoza, Brian Bernal Alferes, Kevin Zambrano Zambrano, Julio Martinez Salazar, Carlos Haroldo Ixcamparij Rosales","doi":"10.1007/s11897-024-00682-w","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review focuses on the association between RA and heart failure, highlighting the role of inflammation and the prevalence of heart failure with preserved ejection fraction (HFpEF) in this population.Recent findings: The incidence of heart failure in RA patients is two to three times higher than in the general population, with inflammation playing a significant role independent of traditional cardiovascular risk factors. HFpEF accounts for about half of heart failure cases and is increasingly recognized in RA patients, although it remains underdiagnosed. Atypical presentations and non-specific symptoms further complicate diagnosis. Early control of inflammation has been shown to reduce the risk of heart failure development and progression, improving both morbidity and mortality outcomes. Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting approximately 1% of the population, with cardiovascular disease being the leading cause of premature death in these patients.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"530-540"},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00682-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review focuses on the association between RA and heart failure, highlighting the role of inflammation and the prevalence of heart failure with preserved ejection fraction (HFpEF) in this population.

Recent findings: The incidence of heart failure in RA patients is two to three times higher than in the general population, with inflammation playing a significant role independent of traditional cardiovascular risk factors. HFpEF accounts for about half of heart failure cases and is increasingly recognized in RA patients, although it remains underdiagnosed. Atypical presentations and non-specific symptoms further complicate diagnosis. Early control of inflammation has been shown to reduce the risk of heart failure development and progression, improving both morbidity and mortality outcomes. Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting approximately 1% of the population, with cardiovascular disease being the leading cause of premature death in these patients.

查看原文本刊更多论文

类风湿性关节炎的心力衰竭：临床意义。

综述的目的：这篇综述重点探讨了RA与心力衰竭之间的关联，强调了炎症的作用以及射血分数保留型心力衰竭（HFpEF）在这一人群中的发病率：最近的研究结果：RA 患者心力衰竭的发病率是普通人群的两到三倍，炎症在传统的心血管风险因素之外发挥着重要作用。HFpEF约占心力衰竭病例的一半，在RA患者中的认知度越来越高，但仍未得到充分诊断。不典型的表现和非特异性症状使诊断更加复杂。研究表明，早期控制炎症可降低心衰发生和发展的风险，从而改善发病率和死亡率。类风湿性关节炎（RA）是一种全身性炎症性疾病，影响着约1%的人口，心血管疾病是这些患者过早死亡的主要原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.